Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesTeneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesDipeptidyl peptidase-4 and kidney fibrosis in diabetesStrategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational StudiesPotentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusDrug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysisSafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewA nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patientsTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsSafety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trialsβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseAlogliptin benzoate for management of type 2 diabetesDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsAddition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysisAllosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptorCardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemAcute myocardial infarction associated to DPP-4 inhibitorsShort- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients.Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32).Emerging gliptins for type 2 diabetes.Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis.A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysisImportance of Beta Cell Function for the Treatment of Type 2 DiabetesSitagliptin: Is It Effective in Routine Clinical Practice?Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.
P2860
Q22241288-8F7AC23F-EF8B-475B-A5D0-BC4B7E59ED81Q24568148-0913E018-7C1C-4694-BA5E-6BB42373C92AQ24628948-7AEF3893-C723-43EB-BF2B-D8C153E9EAE2Q26765047-3E3F2EE9-856C-481F-8073-29087C02E25DQ26766089-B2AE4956-DB5E-4DCB-BF82-4A513CA0C8A2Q26772054-4309D4CC-B488-43F2-B36D-74A4A0AFD197Q26774021-51386428-195A-4C5F-9F03-357078885C36Q26784192-0E86B56A-226C-442A-B2CA-4041D56FB6F1Q26863262-DE67BAE8-1E71-42C2-B11C-28B05813CAD4Q26995462-9E5B651C-1167-40E6-B1B4-B078F229DE1EQ27021870-FAC5DBD8-21CB-4D27-847A-592DC69F3685Q27022613-37E8570A-5BF5-4D85-ADF8-FD37A6281478Q27692665-59B0241F-D2F3-48EF-842D-0DB067D4BE2EQ28069065-A4521F6C-768A-4C1C-A040-887BDC998DA5Q28083933-4E9FDB93-292B-4D31-85CE-533B720FE362Q28238585-98177CD5-9E02-49BB-85AE-5493E468CDDCQ28275281-5A8623FD-3891-4DB7-9680-5982FF44CAB9Q28484498-A4846548-4AD7-46FB-8C2D-2AF141138BF1Q30241808-47ABDCE4-50A1-4B27-825C-DD723731F2C7Q30249371-1E5BE317-68B6-4C92-B482-4AAD0ABBC44EQ30631209-F3850109-78F9-4CBA-AACA-F8EEF0189CFAQ33775785-1C96E6A4-33A5-4F47-A38E-D843A87B615FQ33999894-6EEBDDDA-7214-4A81-AF6E-EA679F433976Q34062829-5045830F-0464-4D90-A204-19F0185CCE57Q34272594-A8683CDD-90FF-4A00-A046-3D24F03B2975Q34299647-18C37A12-D2C5-4A56-B366-457B3A18AA41Q34299670-B5EEDB8A-CB5F-41EC-99E2-DE10667183A5Q34347884-EB72C2A3-C522-4C7E-A044-F2A32E2BEC8CQ34559981-52E5E898-B3E9-4295-924A-B6FBC1A6FB6DQ34681579-B2461EC8-A642-4D02-B092-2B9C387357ABQ34783302-3752E666-3B90-4E9F-BFC7-D8C1CDFDD977Q34917515-A9D67DD0-7F7F-4503-8B88-5656E91FB77AQ35073584-67D0791F-682C-4C8A-A3B2-B9B6099A9DCFQ35225372-921DEA8D-3CFD-4987-ABBD-63CBF1D58623Q35236019-52F14BAD-FA79-4416-A0C4-7D40F3BC0EE6Q35382193-C599B68D-A2BA-4F70-B8D6-5730653AD2C2Q35667116-D4768825-0492-483F-930A-64A51DE8B709Q35671855-FDA66848-5690-4226-B6F0-49BBCC528F82Q35808043-3E031CC1-BBB2-4907-BF27-E6BF4FB66786Q35964678-81FAA2A5-208B-47A9-926E-AFA7FB12276F
P2860
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@ast
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@en
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@nl
type
label
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@ast
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@en
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@nl
prefLabel
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@ast
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@en
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@nl
P2093
P356
P1433
P1476
Dipeptidyl peptidase-4 inhibit ...... atic review and meta-analysis.
@en
P2093
David R Matthews
Konstantinos Paletas
Paschalis Paschos
P356
10.1136/BMJ.E1369
P407
P577
2012-03-12T00:00:00Z